Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia

NCT00795756 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

145

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG: liposome-encapsulated cytarabine (DepoCyte)
DRUG: Triple intrathecal therapy (TIT)

Sponsor

Northern Italy Leukemia Group